<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mortalin/GRP75 is a ubiquitous <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> chaperone related to the cytosolic heat shock protein 70 (HSP70) </plain></SENT>
<SENT sid="1" pm="."><plain>It protects cells from senescence and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and is overexpressed in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>Cell resistance to complement-dependent cytotoxicity depends on mortalin and during complement attack mortalin is released from cells </plain></SENT>
<SENT sid="3" pm="."><plain>Our goal was to determine whether <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients have circulating mortalin in blood </plain></SENT>
<SENT sid="4" pm="."><plain>The significance of mortalin in blood to survival prospects of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients was evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>Occurrence of extracellular soluble HSP70 (sHSP70) is documented </plain></SENT>
<SENT sid="6" pm="."><plain>We developed a sensitive ELISA for mortalin </plain></SENT>
<SENT sid="7" pm="."><plain>The association between mortalin level and survival was subjected to the Cox proportional hazards analysis (univariate and multivariate analyses) </plain></SENT>
<SENT sid="8" pm="."><plain>Mortalin concentration in serum of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients was 10-214 ng/ml </plain></SENT>
<SENT sid="9" pm="."><plain>Survival data of the patients were known from an earlier study of sHSP70 in these samples </plain></SENT>
<SENT sid="10" pm="."><plain>Cox regression analysis indicated that high mortalin (&gt;60 ng/ml) is a risk factor for shorter survival </plain></SENT>
<SENT sid="11" pm="."><plain>Serum levels of sHSP70 and mortalin in patients were independent variables </plain></SENT>
<SENT sid="12" pm="."><plain>Concurrence of high sHSP70 and mortalin was associated with rapid disease progression (HR = 4, 2.04-8.45, p &lt; 0.001) </plain></SENT>
<SENT sid="13" pm="."><plain>Addition of high sHSP70 and mortalin to a baseline model of age, sex and TNM stage, significantly (p &lt; 0.001) enhanced the risk score to 8 (3.26-20.46) </plain></SENT>
<SENT sid="14" pm="."><plain>This is the first demonstration of circulating mortalin in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients </plain></SENT>
<SENT sid="15" pm="."><plain>Analysis of mortalin in blood, and even more so of mortalin and sHSP70, adds a high prognostic value to the TNM stage and will identify <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients at high risk of poor survival </plain></SENT>
</text></document>